The Indian Supreme Court has failed to provide the clarity which is craved by practitioners in its latest pronouncement on the controversial Section 3(d), says Jitesh Kumar.
Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report.
Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains.
The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews.
It’s been a long time coming, but perhaps the Brazilian patent office is finally going to deal with the logjam of patent applications, says Gabriel di Blasi.
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.
Susana Soares is a designer inspired by scientific research to create objects that explore new aesthetic and behavioural opportunities. LSIPR investigated how she protects her work in a realm where life sciences and design collide.
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.
Three December decisions from the Court Of Justice of the European Union shed light on supplementary protection certificates in Europe.
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande.